Joan Brunet

List of Publications by Year in descending order

186 papers	7,950 citations	57758 44 h-index	69250 77 g-index
199 all docs	199 docs citations	199 times ranked	13259 citing authors

#	Article	IF	Citations
1	Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2022, 20, 611-621.e9.	4.4	17
2	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
3	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	7.1	50
4	DGCR8 and the six hit, three-step model of schwannomatosis. Acta Neuropathologica, 2022, 143, 115-117.	7.7	10
5	Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Ageâ€“Periodâ€“Cohort Modelling. International Journal of Environmental Research and Public Health, 2022, 19, 1404.	2.6	4
6	Potential Involvement of NSD1, KRT24 and ACACA in the Genetic Predisposition to Colorectal Cancer. Cancers, 2022, 14, 699.	3.7	0
7	Mosaicism in PTENâ€”new case and comment on the literature. European Journal of Human Genetics, 2022, 30, 641-644.	2.8	6
8	Night work, chronotype and risk of endometrial cancer in the Screenwide caseâ€“control study. Occupational and Environmental Medicine, 2022, , oemed-2021-108080.	2.8	6
9	Modification of BRCA1-associated breast cancer risk by HMMR overexpression. Nature Communications, 2022, 13, 1895.	12.8	19
10	Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals, 2022, 15, 19.	3.8	2
11	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. Journal of the National Cancer Institute, 2022, 114, 979-987.	6.3	14
12	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. European Journal of Cancer, 2022, 170, 10-16.	2.8	11
13	Vaccination against SARS-CoV-2 protects from morbidity, mortalityÂand sequelae from COVID19 in patients with cancer. European Journal of Cancer, 2022, 171, 64-74.	2.8	19
14	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncology, The, 2022, 23, 865-875.	10.7	50
15	An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide) Tj ETQq1 1 0.784314 rgBT /Overloc	2.5	6
16	TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes. Gut, 2021, 70, 1139-1146.	12.1	10
17	Predicting the rising incidence and mortality of endometrial cancers among women aged 65-74 years in Catalonia. Maturitas, 2021, 144, 11-15.	2.4	2
18	Characteristics of Adrenocortical Carcinoma Associated With Lynch Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 318-325.	3.6	20

#	Article	IF	Citations
19	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110422.	3.2	4
20	BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort. Genes, 2021, 12, 150.	2.4	11
21	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
22	Patientsâ€™ and professionalsâ€™ perspective of non-in-person visits in hereditary cancer: predictors and impact of the COVID-19 pandemic. Genetics in Medicine, 2021, 23, 1450-1457.	2.4	1
23	Response to letter entitled: Re: ERCC3 a new ovarian cancer susceptibility gene?. European Journal of Cancer, 2021, 150, 281-282.	2.8	0
24	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. European Journal of Cancer, 2021, 150, 190-202.	2.8	37
25	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
26	Non-Lynch Familial and Early-Onset Colorectal Cancer Explained by Accumulation of Low-Risk Genetic Variants. Cancers, 2021, 13, 3857.	3.7	8
27	Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants. Human Mutation, 2021, 42, 1488-1502.	2.5	7
28	Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancerâ€“Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. Journal of Molecular Diagnostics, 2021, 23, 1452-1459.	2.8	10
29	Sensitivity of cervical cytology in endometrial cancer detection in a tertiary hospital in Spain. Cancer Medicine, 2021, 10, 6762-6766.	2.8	6
30	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	10.7	73
31	RNA assay identifies a previous misclassification of BARD1 c.1977A>G variant. Scientific Reports, 2021, 11, 22948.	3.3	0
32	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
33	The â€œPsychosocial Aspects in Hereditary Cancerâ€•questionnaire in women attending breast cancer genetic clinics: Psychometric validation across Frenchâ€, Germanâ€•and Spanishâ€language versions. European Journal of Cancer Care, 2020, 29, e13173.	1.5	2
34	Complete Loss of EPCAM Immunoexpression Identifies EPCAM Deletion Carriers in MSH2-Negative Colorectal Neoplasia. Cancers, 2020, 12, 2803.	3.7	4
35	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers, 2020, 12, 1841.	3.7	58
36	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82

#	Article	IF	Citations
37	Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals. Cancers, 2020, 12, 1799.	3.7	15
38	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. Scientific Reports, 2020, 10, 7741.	3.3	9
39	Screening of CNVs using NGS data improves mutation detection yield and decreases costs in genetic testing for hereditary cancer. Journal of Medical Genetics, 2020, , jmedgenet-2020-107366.	3.2	3
40	Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals. Cancers, 2020, 12, 3419.	3.7	11
41	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discovery, 2020, 10, 1465-1474.	9.4	151
42	Immune Cell Associations with Cancer Risk. IScience, 2020, 23, 101296.	4.1	6
43	Role of POLE and POLD1 in familial cancer. Genetics in Medicine, 2020, 22, 2089-2100.	2.4	76
44	ERCC3, a new ovarian cancer susceptibility gene?. European Journal of Cancer, 2020, 141, 1-8.	2.8	8
45	Comprehensive analysis and ACMGâ€based classification of CHEK2 variants in hereditary cancer patients. Human Mutation, 2020, 41, 2128-2142.	2.5	10
46	High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers. Journal of Medical Genetics, 2020, 57, 269-273.	3.2	20
47	Evaluation of CNV detection tools for NGS panel data in genetic diagnostics. European Journal of Human Genetics, 2020, 28, 1645-1655.	2.8	67
48	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 1770.	2.4	42
49	Sensitivity of cervicoâ€vaginal cytology in endometrial carcinoma: A systematic review and metaâ€analysis. Cancer Cytopathology, 2020, 128, 792-802.	2.4	23
50	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with <scp>PARP</scp> inhibitors. EMBO Molecular Medicine, 2020, 12, e11217.	6.9	37
51	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. Journal of Thoracic Oncology, 2020, 15, 1232-1239.	1.1	29
52	The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases. Cancers, 2020, 12, 292.	3.7	11
53	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer, 2020, 132, 53-60.	2.8	16
54	Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients. Cancers, 2020, 12, 829.	3.7	41

#	Article	IF	Citations
55	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging, 2020, 12, 8-34.	3.1	99
56	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging, 2020, 12, 4794-4814.	3.1	38
57	Improving Genetic Testing in Hereditary Cancer by RNA Analysis. Journal of Molecular Diagnostics, 2020, 22, 1453-1468.	2.8	9
58	Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study. BMJ Open, 2019, 9, e029926.	1.9	9
59	Germline variation in O6-methylguanine-DNA methyltransferase (MGMT) as cause of hereditary colorectal cancer. Cancer Letters, 2019, 447, 86-92.	7.2	12
60	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
61	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
62	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
63	NTHL1 biallelic mutations seldom cause colorectal cancer, serrated polyposis or a multi-tumor phenotype, in absence of colorectal adenomas. Scientific Reports, 2019, 9, 9020.	3.3	23
64	Contribution to colonic polyposis of recently proposed predisposing genes and assessment of the prevalence of NTHL1 â€•and MSH3 â€associated polyposes. Human Mutation, 2019, 40, 1910-1923.	2.5	24
65	Defining a mutational signature for endometrial cancer screening and early detection. Cancer Epidemiology, 2019, 61, 129-132.	1.9	7
66	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. Food and Chemical Toxicology, 2019, 131, 110529.	3.6	15
67	New perspectives on screening and early detection of endometrial cancer. International Journal of Cancer, 2019, 145, 3194-3206.	5.1	58
68	The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. Frontiers in Oncology, 2019, 9, 193.	2.8	17
69	Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. International Journal of Cancer, 2019, 145, 2682-2691.	5.1	30
70	The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. Food and Chemical Toxicology, 2019, 128, 35-45.	3.6	27
71	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of Clinical Medicine, 2019, 8, 2180.	2.4	12
72	Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation. Clinical Epigenetics, 2019, 11, 171.	4.1	7

#	Article	IF	Citations
73	Does multilocus inherited neoplasia alleles syndrome have severe clinical expression?. Journal of Medical Genetics, 2019, 56, 521-525.	3.2	11
74	NovelPOLEpathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. Human Mutation, 2019, 40, 36-41.	2.5	21
75	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
76	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. Aging, 2019, 11, 2874-2888.	3.1	25
77	Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1. Nature Communications, 2018, 9, 967.	12.8	33
78	Evidence suggests that germline RNF43 mutations are a rare cause of serrated polyposis. Gut, 2018, 67, 2230-2232.	12.1	48
79	Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer. Gastroenterology, 2018, 154, 181-194.e20.	1.3	32
80	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. Frontiers in Endocrinology, 2018, 9, 657.	3.5	85
81	Surveillance Guidelines for Hereditary Colorectal Cancer Syndromes. , 2018, , 305-326.		0
82	Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are infrequent in familial colorectal cancer and polyposis. Molecular Cancer, 2018, 17, 23.	19.2	19
83	Elucidating the molecular basis of MSH2â€deficient tumors by combined germline and somatic analysis. International Journal of Cancer, 2017, 141, 1365-1380.	5.1	26
84	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
85	Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. Scientific Reports, 2017, 7, 37984.	3.3	35
86	A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. Scientific Reports, 2017, 7, 39348.	3.3	45
87	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene, 2017, 36, 2737-2749.	5.9	34
88	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
89	Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nature Communications, 2017, 8, 15908.	12.8	118
90	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152

#	Article	IF	Citations
91	BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget, 2017, 8, 35019-35032.	1.8	12
92	Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer. Oncotarget, 2017, 8, 74391-74405.	1.8	40
93	Ethics competences in the undergraduate medical education curriculum: the Spanish experience. Croatian Medical Journal, 2016, 57, 493-503.	0.7	11
94	Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget, 2016, 7, 32006-32014.	1.8	47
95	Somatic DICER1 mutations in adult-onset pulmonary blastoma. European Respiratory Journal, 2016, 47, 1879-1882.	6.7	22
96	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327.	2.5	26
97	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
98	Scarce evidence of the causal role of germline mutations in UNC5C in hereditary colorectal cancer and polyposis. Scientific Reports, 2016, 6, 20697.	3.3	9
99	Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA. Breast Cancer Research and Treatment, 2016, 155, 253-260.	2.5	6
100	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
101	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77
102	POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genetics in Medicine, 2016, 18, 325-332.	2.4	209
103	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
104	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget, 2016, 7, 82185-82199.	1.8	16
105	Mammographic density and breast cancer in women from high risk families. Breast Cancer Research, 2015, 17, 93.	5.0	22
106	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
107	SEOM clinical guidelines in Hereditary Breast and ovarian cancer. Clinical and Translational Oncology, 2015, 17, 956-961.	2.4	82
108	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221

#	Article	IF	Citations
109	Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair. Gastroenterology, 2015, 149, 563-566.	1.3	94
110	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
111	Integrating gene expression and epidemiological data for the discovery of genetic interactions associated with cancer risk. Carcinogenesis, 2014, 35, 578-585.	2.8	1
112	VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research, 2014, 16, R53.	5.0	28
113	GALNT12is Not a Major Contributor of Familial Colorectal Cancer Type X. Human Mutation, 2014, 35, 50-52.	2.5	22
114	New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Human Molecular Genetics, 2014, 23, 3506-3512.	2.9	135
115	Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung Cancer, 2014, 86, 102-104.	2.0	27
116	Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. European Journal of Cancer, 2014, 50, 2241-2250.	2.8	66
117	Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient. Anticancer Research, 2014, 34, 4323-7.	1.1	21
118	Refining the role ofpms2in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants. Journal of Medical Genetics, 2013, 50, 552-563.	3.2	47
119	Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. European Journal of Human Genetics, 2013, 21, 864-870.	2.8	94
120	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
121	Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases. PLoS ONE, 2013, 8, e67538.	2.5	44
122	Functional and Structural Analysis of C-Terminal BRCA1 Missense Variants. PLoS ONE, 2013, 8, e61302.	2.5	16
123	Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. British Journal of Cancer, 2012, 106, 1406-1414.	6.4	42
124	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	2.5	47
125	MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. European Journal of Human Genetics, 2012, 20, 762-768.	2.8	76
126	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513

#	Article	IF	Citations
127	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. Oncology Reports, 2012, 27, 1887-92.	2.6	5
128	MLH1 methylation screening is effective in identifying epimutation carriers. European Journal of Human Genetics, 2012, 20, 1256-1264.	2.8	36
129	Cancer develops, progresses and responds to therapies through restricted perturbation of the proteinâ€“protein interaction network. Integrative Biology (United Kingdom), 2012, 4, 1038.	1.3	10
130	What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?. Breast, 2012, 21, 755-760.	2.2	36
131	Comprehensive functional assessment ofMLH1variants of unknown significance. Human Mutation, 2012, 33, 1576-1588.	2.5	30
132	Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Research and Treatment, 2012, 132, 979-992.	2.5	20
133	Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families. BMC Cancer, 2012, 12, 84.	2.6	14
134	Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Research and Treatment, 2012, 132, 307-315.	2.5	50
135	Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Investigational New Drugs, 2012, 30, 846-852.	2.6	11
136	Neuroendocrine tumors: A population-based study of incidence and survival in Girona province, 1994â€“2004. Cancer Epidemiology, 2011, 35, e49-e54.	1.9	20
137	Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochemical and Biophysical Research Communications, 2011, 407, 412-419.	2.1	44
138	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	5.0	23
139	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (ErbituxÃ¯Â¿Â½) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. International Journal of Oncology, 2011, 39, 1455-79.	3.3	15
140	Costs and Ethical Issues Related to First-Line Treatment of Metastatic Nonâ€“Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective. Clinical Lung Cancer, 2011, 12, 335-340.	2.6	2
141	eXiT*CBR: A framework for case-based medical diagnosis development and experimentation. Artificial Intelligence in Medicine, 2011, 51, 81-91.	6.5	31
142	Evidence for a link between TNFRSF11A and risk of breast cancer. Breast Cancer Research and Treatment, 2011, 129, 947-954.	2.5	12
143	Identification of a new complex rearrangement affecting exon 20 of BRCA1. Breast Cancer Research and Treatment, 2011, 130, 341-344.	2.5	3
144	SEOM clinical guidelines for hereditary cancer. Clinical and Translational Oncology, 2011, 13, 580-586.	2.4	13

#	Article	IF	Citations
145	Stem cell property epithelialâ€toâ€mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbituxâ„¢) efficacy in KRAS wildâ€type tumor cells. Journal of Cellular Biochemistry, 2011, 112, 10-29.	2.6	41
146	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	5.6	91
147	Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes. Breast Cancer Research and Treatment, 2010, 122, 733-743.	2.5	34
148	Hereditary breast cancer and genetic counseling in young women. Breast Cancer Research and Treatment, 2010, 123, 7-9.	2.5	10
149	Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain. Familial Cancer, 2010, 9, 297-304.	1.9	32
150	Exploring the Link between Germline and Somatic Genetic Alterations in Breast Carcinogenesis. PLoS ONE, 2010, 5, e14078.	2.5	33
151	MLH1 Founder Mutations with Moderate Penetrance in Spanish Lynch Syndrome Families. Cancer Research, 2010, 70, 7379-7391.	0.9	29
152	Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochemical and Biophysical Research Communications, 2010, 397, 27-33.	2.1	60
153	CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD). International Journal of Gynecological Cancer, 2010, 20, 87-91.	2.5	8
154	Identification of a Novel Pathogenic Mutation in BRCA2 in a Spanish Breast-Ovarian Cancer Family. Genetic Testing and Molecular Biomarkers, 2009, 13, 631-634.	0.7	0
155	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	6.4	15
156	Genome-wide Linkage Scan Reveals Three Putative Breast-Cancer-Susceptibility Loci. American Journal of Human Genetics, 2009, 84, 115-122.	6.2	30
157	Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Human Reproduction, 2009, 24, 1772-1772.	0.9	0
158	Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. International Journal of Oncology, 2009, 35, 1369-76.	3.3	19
159	Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Research and Treatment, 2008, 109, 471-479.	2.5	98
160	Giacomo Castelvetroâ€™s salads. Anti-HER2 oncogene nutraceuticals since the 17th century?. Clinical and Translational Oncology, 2008, 10, 30-34.	2.4	17
161	BRCA1 and acetylâ€CoA carboxylase: The metabolic syndrome of breast cancer. Molecular Carcinogenesis, 2008, 47, 157-163.	2.7	65
162	ATM germline mutations in Spanish earlyâ€onset breast cancer patients negative for BRCA1/BRCA2 mutations. Clinical Genetics, 2008, 73, 465-473.	2.0	19

#	Article	IF	Citations
163	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Proliferation, 2008, 41, 59-85.	5.3	160
164	Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Human Reproduction, 2008, 24, 1000-1006.	0.9	61
165	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (TykerbÂ®) in human breast carcinoma cells. Annals of Oncology, 2008, 19, 1097-1109.	1.2	39
166	Modeling Reuse on Case-Based Reasoning with Application to Breast Cancer Diagnosis. Lecture Notes in Computer Science, 2008, , 322-332.	1.3	9
167	Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Research, 2008, 28, 3671-6.	1.1	32
168	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncology Reports, 2007, 18, 973.	2.6	24
169	Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptinâ„¢) by transcriptionally inhibiting â€˜HER2 super-expressionâ€™ occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. International Journal of Oncology, 2007, 31, 769.	3.3	15
170	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptinâ„¢) in HER2-overexpressing breast cancer cells. BMC Cancer, 2007, 7, 80.	2.6	154
171	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). International Journal of Molecular Medicine, 2007, 20, 3-10.	4.0	96
172	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncology Reports, 2007, 18, 973-80.	2.6	39
173	Cancer screening and genetic counseling. Clinical and Translational Oncology, 2004, 6, 176-183.	2.4	3
174	EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE. Journal of Urology, 2004, 172, 1256-1261.	0.4	115
175	Prevalence ofBRCA1andBRCA2germline mutations in young breast cancer patients: A population-based study. International Journal of Cancer, 2003, 106, 588-593.	5.1	90
176	Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients. British Journal of Cancer, 1999, 79, 1302-1303.	6.4	43
177	Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 1999, 23, 27-33.	2.4	67
178	BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families. International Journal of Cancer, 1999, 83, 465-469.	5.1	32
179	Two contiguously located germline BRCA1 mutations in a Spanish early-onset breast cancer family. Cancer Letters, 1999, 142, 71-73.	7.2	2
180	Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population. Human Genetics, 1998, 103, 707-708.	3.8	27

#	Article	IF	Citations
181	Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.. Journal of Clinical Oncology, 1995, 13, 1493-1500.	1.6	87
182	Function preservation in stage III squamous laryngeal carcinoma: Results with an induction chemotherapy protocol. Laryngoscope, 1995, 105, 822-826.	2.0	26
183	Chemotherapy And Radiotherapy In Locally Advanced Cervical Cancer. Acta OncolÃ³gica, 1995, 34, 941-944.	1.8	7
184	Chop Chemotherapy of Intermediate and High-Grade Non-Hodgkin's Lymphoma. Acta OncolÃ³gica, 1994, 33, 935-939.	1.8	6
185	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressaâ„¢)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). International Journal of Molecular Medicine, 0, , .	4.0	31
186	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling. International Journal of Oncology, 0, , .	3.3	14